Clinical Impact of Donor Milk Pasteurized by HTST Treatment in Preterm Infants
Primary Purpose
Late-Onset Neonatal Sepsis
Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
donor milk
Sponsored by
About this trial
This is an interventional prevention trial for Late-Onset Neonatal Sepsis focused on measuring neonatal sepsis, extremely low birth weight infant, donor milk, HTST pasteurization, Holder pasteurization
Eligibility Criteria
Inclusion Criteria (all criteria are necessary) :
- Infants weighing 1000 grams or less at birth
- Infants born or transferred before the third day of life to the participating centers
- Start enteral feeding in the first week of life
- Receive any amount of donor milk in the first 28 days of life
- Informed consent signed by parents or legal guardians
Exclusion Criteria:
- Language barrier
- Infants with chromosomopathies
- Infants with major congenital malformations
- Infants with severe asphyxiation (cord pH or first arterial pH <7)
- Infants included in another clinical trial that modifies nutritional management
- Infants who previously fed with formula
Post-randomization exclusion criteria:
- Randomized infant who do not fulfill inclusion criteria
Sites / Locations
- Hospital 12 de Octubre
- Hospital Universitario La Paz
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Holder pasteurization
HTST pasteurization
Arm Description
Donor milk pasteurized by Holder method (62.5ºC, 30 minutes)
Donor milk pasteurized by High Temperature Short Time (HTST) method (72ºC, 15 seconds)
Outcomes
Primary Outcome Measures
Microbiological proven late onset sepsis rate
Incidence of Microbiological proven late onset sepsis expressed as a percentage
Secondary Outcome Measures
Central line associated bloodstream infections (CLABSI) rate
Number of CLABSI events per 1000 catheter-days
Necrotizing enterocolitis (NEC) and/or microbiological proven late onset sepsis rate
Incidence of NEC nad late onset sepsis as a percentage
Mortality rate
Percentage of preterm infant died during the study
Oxygen supplementation
Percentage of infants with respiratory assistance with fraction of inspired oxygen greater than 0.21 at 36 weeks postmenstrual age
Stage 3-5 Retinopathy
Percentage of infants diagnosed with retinopathy by the ophthalmologist
Growth velocity
Growth calculated as the weight gain in g/kg/day
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04424667
Brief Title
Clinical Impact of Donor Milk Pasteurized by HTST Treatment in Preterm Infants
Official Title
Clinical and Economic Impact of Supplementation With Donor Milk Pasteurized by HTST Method Versus Holder Method in Extremely Birth Weight Preterm Infants. Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
June 15, 2020 (Actual)
Primary Completion Date
May 30, 2023 (Actual)
Study Completion Date
September 15, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Carmen Rosa Pallas
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Randomized double-blind clinical trial to compare the incidence of microbiological proven late onset sepsis in extremely preterm infants (<1000 grams) that are supplemented with donor milk pasteurized by High Temperature Short Time (HTST) method versus the Holder method.
Detailed Description
Donor milk pasteurized by an innovative High Temperature Short Time (HTST) system (patented by researchers) retains more immune and trophic compounds than pasteurized milk by traditional Holder method. These compounds are related to the protection conferred by breast milk against nosocomial sepsis and necrotizing enterocolitis in preterm infants, so it would be of interest to study if there is a clinical benefit in these patients when health professionals are supplementing with donor milk pasteurized by both methods.
The purpose of this study is to compare the incidence of microbiological proven late onset sepsis in newborns under 1000 grams that in the first 28 days of life need to be supplemented with donor milk pasteurized by HTST method versus the Holder method.
This is a randomized double-blind clinical trial with parallel assignment. A total of 305 premature babies with a birth weight of less than 1000 grams will be recruited, admitted to the Neonatology Services of the Hospital 12 de Octubre and the Hospital de La Paz and meet the inclusion criteria. Half of the patients will be supplemented exclusively with donor milk pasteurized by the HTST system and the other half with pasteurized milk by the Holder method. Linear generalized models will be used for longitudinal data analysis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Late-Onset Neonatal Sepsis
Keywords
neonatal sepsis, extremely low birth weight infant, donor milk, HTST pasteurization, Holder pasteurization
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Parallel assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
211 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Holder pasteurization
Arm Type
Active Comparator
Arm Description
Donor milk pasteurized by Holder method (62.5ºC, 30 minutes)
Arm Title
HTST pasteurization
Arm Type
Experimental
Arm Description
Donor milk pasteurized by High Temperature Short Time (HTST) method (72ºC, 15 seconds)
Intervention Type
Other
Intervention Name(s)
donor milk
Intervention Description
pasteurized donor milk
Primary Outcome Measure Information:
Title
Microbiological proven late onset sepsis rate
Description
Incidence of Microbiological proven late onset sepsis expressed as a percentage
Time Frame
From the time and day of randomization until the date of discharge from the neonatal unit, assessed up to 24 weeks
Secondary Outcome Measure Information:
Title
Central line associated bloodstream infections (CLABSI) rate
Description
Number of CLABSI events per 1000 catheter-days
Time Frame
From the time and day of randomization until the date of discharge from the neonatal unit, assessed up to 24 weeks
Title
Necrotizing enterocolitis (NEC) and/or microbiological proven late onset sepsis rate
Description
Incidence of NEC nad late onset sepsis as a percentage
Time Frame
From the time and day of randomization until the date of discharge from the neonatal unit, assessed up to 24 weeks
Title
Mortality rate
Description
Percentage of preterm infant died during the study
Time Frame
From the time and day of randomization until the date of discharge from the neonatal unit, assessed up to 24 weeks
Title
Oxygen supplementation
Description
Percentage of infants with respiratory assistance with fraction of inspired oxygen greater than 0.21 at 36 weeks postmenstrual age
Time Frame
Assessed up to 24 weeks
Title
Stage 3-5 Retinopathy
Description
Percentage of infants diagnosed with retinopathy by the ophthalmologist
Time Frame
From the time and day of randomization until the date of discharge from the neonatal unit, assessed up to 24 weeks
Title
Growth velocity
Description
Growth calculated as the weight gain in g/kg/day
Time Frame
Assessed up to 24 weeks
10. Eligibility
Sex
All
Maximum Age & Unit of Time
28 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria (all criteria are necessary) :
Infants weighing 1000 grams or less at birth
Infants born or transferred before the third day of life to the participating centers
Start enteral feeding in the first week of life
Receive any amount of donor milk in the first 28 days of life
Informed consent signed by parents or legal guardians
Exclusion Criteria:
Language barrier
Infants with chromosomopathies
Infants with major congenital malformations
Infants with severe asphyxiation (cord pH or first arterial pH <7)
Infants included in another clinical trial that modifies nutritional management
Infants who previously fed with formula
Post-randomization exclusion criteria:
- Randomized infant who do not fulfill inclusion criteria
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carmen Rosa Pallas Alonso
Organizational Affiliation
Hospital Universitario 12 de Octubre
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Hospital Universitario La Paz
City
Madrid
ZIP/Postal Code
28046
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Clinical Impact of Donor Milk Pasteurized by HTST Treatment in Preterm Infants
We'll reach out to this number within 24 hrs